pharmaphorum

MARCH 14, 2022

AstraZeneca has failed in its bid to get US approval for its IL-5 inhibitor Fasenra as a treatment for chronic rhinosinusitis in people with nasal polyps, after the FDA rejected its marketing application. The US regulator has asked for additional clinical data, according to AZ, which said it remains committed to brining the drug to patients with the inflammatory condition, which results in the growth of nasal polyps in the nose that can sometimes require surgical intervention.

FDA 115

FDA 115

Outsourcing Pharma

MARCH 14, 2022

The pharma company and academic institution will explore the viability of a psychedelic treatment to help patients suffering from cancer-related distress.

122

122

pharmaphorum

MARCH 14, 2022

Janssen’s Roz Bekker, VP Commercial Strategy for Infectious Diseases & Vaccines at Janssen EMEA, looks at how COVID-19 has reinforced the value of connecting with people, and how healthcare systems need ongoing reform to deliver more holistic, human-centric care. The connecting effect of COVID-19. No matter where you are in the world, COVID-19 has had an impact.

Vaccines 95

Vaccines Pharmaceutical Companies Pharmaceutical Companies Hospitals 95

Outsourcing Pharma

MARCH 14, 2022

An executive from the AI specialist discusses how recent advances have provided opportunities for industry professionals to champion new ways of thinking.

107

107

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

pharmaphorum

MARCH 14, 2022

Novartis may be planning to sell off its generics business Sandoz, but that hasn’t stopped it investing in the unit ahead of a decision on its future later this year. This morning, Sandoz announced it has acquired medical and drug delivery device specialist Coalesce Product Development, bolstering its capabilities for the development of respiratory medicines and ‘complex’ generics.

Generic Medicine 91

Generic Medicine 91

Birth Control Pharmacist

MARCH 14, 2022

Can pharmacy students advocate for pharmacists prescribing hormonal contraceptives? YES, that is exactly what Wilson Pace , a graduate of the University of Utah College of Pharmacy did. When Wilson heard about the barriers and costs that women experience when accessing contraceptives. His perseverance and dedication to advocacy as a pharmacy student allowed him to take action in his leadership class.

52

52

Pharma Marketing Network

MARCH 14, 2022

Tune in and watch the Pharma Marketing Network and industry experts from Novo Nordisk, Eisai, GSK, Otsuka, and more during part 1 of a 2 part series on engagement. This PMN HCP Engagement Summit focused HCP Engagement throughout the following panels: Modular Content: Making It Work. Get insights for pharma marketing insiders on restructuring your content strategy allowing more flexibility and agility to deliver more relative content to your customers.

52

52

pharmaphorum

MARCH 14, 2022

Four years ago, Bristol-Myers Squibb paid $1.85 billion upfront to claim rights to Nektar’s bempegaldesleukin, setting it up to be companion drug to its cancer immunotherapy Opdivo. Now, that hope is looking like a bust. The PIVOT IO-001 trial of Opdivo (nivolumab) plus bempeg as a first-line treatment for advanced melanoma showed no improvement over Opdivo alone on progression-free survival and the objective response rate at the final analysis, or overall survival on an interim assessment

FDA 52

FDA 52

Outsourcing Pharma

MARCH 14, 2022

During Outsourcing-Pharmaâs March 23 webinar, Clinical Development Advances, leaders from different areas will share innovative technology and practices.

52

52

pharmaphorum

MARCH 14, 2022

After two years of virtual events, the PM Society celebrated its 36th annual awards with an in-person ceremony at London’s Grosvenor House on Friday 11 March. The event brought together some of the best and brightest minds working across creative communications in pharma and healthcare. There were two stand-out winners at this year’s awards. Topping the leader board was 21GRAMS, part of Real Chemistry, which took home six gold, two silver and one bronze award for its work on Slow the Burn (Novar

Communication 52

Communication 52

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

Pharma Times

MARCH 14, 2022

In the coming months, an additional vaccine booster will be offered to those over 75, care home residents and to those over 12 who are most vulnerable

Vaccines 46

Vaccines 46

pharmaphorum

MARCH 14, 2022

[link]. Sponsored by: CHDR. Conference Chairman: Richard Malamut, Chief Medical Officer, Collegium Pharmaceutical, Inc. Novel Compounds and Treatments for Pain: Opioids and the Alternatives. SMi’s 22nd Pain Therapeutics Conference will cover the leading advances in pain therapeutics, exploring late development clinical trials, novel treatments for chronic conditions, technology collaboration treatments, using VR and Medical Devices that carry out non-invasive nerve stimulation.

Compounding 52

Compounding 52

Pharma Times

MARCH 14, 2022

Site will include creating space for student accommodation, offices, retail outlets and restaurants

35

35

pharmaphorum

MARCH 14, 2022

Prescription digital therapeutics (DTx) company Blue Note is starting a large-scale, decentralised trial of two cancer therapies that it hopes will lead to regulatory approval from the FDA. The company is working with Curebase on a trial that will recruit around 350 patients with cancer and will be run completely remotely, with no need for clinic visits.

Chemotherapy 52

Chemotherapy FDA 52

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software